Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

Gianluigi Ferretti, Emilio Bria, Diana Giannarelli, Paolo Carlini, Alessandra Felici, Mario Mandalà, Paola Papaldo, Alessandra Fabi, Mariangela Ciccarese, Federica Cuppone, Fabiana Letizia Cecere, Carmen Nuzzo, Edmondo Terzoli, Francesco Cognetti

Research output: Contribution to journal › Article

Abstract

Purpose: To evaluate whether the incidence of recurrent venous thromboembolism (VTE) events after therapy differs for patients treated with long-term low-molecular-weight heparin (LMWH) or oral anticoagulant therapy (OAT). Methods: All randomized studies were searched through computerized queries of MEDLINE, the Cochrane Controlled Trials Register, the American Society of Hematology abstract database, and the American Society of Clinical Oncology abstract database. Results: Eleven studies including 2,907 patients were identified. Seven studies evaluated a period of 3 to 9 months after cessation of the allocated treatment: 5.4% of patients in the LMWH group vs 4% in the arm allocated to OAT had an episode of recurrent symptomatic VTE. Combined analysis showed a nonsignificant trend in lowering recurrent symptomatic VTE in favor of OAT (relative risk [RR], 1.29; 95% confidence interval [CI], 0.82 to 2.02; p = 0.27). By contrast, during active treatment, a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT was registered (RR, 0.63; 95% CI, 0.47 to 0.83; p = 0.001). Regarding cancer patients only, 37 of 569 patients (6.5%) in the LMWH group had recurrent symptomatic VTE vs 69 of 546 patients (12.6%) in the OAT group, with a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH (RR, 0.52; 95% CI, 0.35 to 0.76; p = 0.001). Conclusions: Despite the significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT during treatment, patients treated with long-term LMWH do not seem to have more frequently recurrent VTE events compared with OAT after cessation of therapy. The significant difference favoring LMWH over OAT among all patients receiving treatment comes mostly from studies enrolling cancer patients.

Original languageEnglish
Pages (from-to)1808-1816
Number of pages9
JournalChest
Volume130
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Low Molecular Weight Heparin
Venous Thromboembolism
Anticoagulants
Risk Reduction Behavior
Therapeutics
Confidence Intervals
Databases
Withholding Treatment
Group Psychotherapy
MEDLINE
Neoplasms

Keywords

  • Deep vein thrombosis
  • Low-molecular-weight heparin
  • Oral anticoagulant therapy
  • Venous thromboembolism
  • Vitamin K antagonists

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? / Ferretti, Gianluigi; Bria, Emilio; Giannarelli, Diana; Carlini, Paolo; Felici, Alessandra; Mandalà, Mario; Papaldo, Paola; Fabi, Alessandra; Ciccarese, Mariangela; Cuppone, Federica; Cecere, Fabiana Letizia; Nuzzo, Carmen; Terzoli, Edmondo; Cognetti, Francesco.

In: Chest, Vol. 130, No. 6, 12.2006, p. 1808-1816.

Research output: Contribution to journal › Article

Ferretti, G, Bria, E, Giannarelli, D, Carlini, P, Felici, A, Mandalà, M, Papaldo, P, Fabi, A, Ciccarese, M, Cuppone, F, Cecere, FL, Nuzzo, C, Terzoli, E & Cognetti, F 2006, 'Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?', Chest, vol. 130, no. 6, pp. 1808-1816. https://doi.org/10.1378/chest.130.6.1808
Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalà M et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest. 2006 Dec;130(6):1808-1816. https://doi.org/10.1378/chest.130.6.1808
Ferretti, Gianluigi ; Bria, Emilio ; Giannarelli, Diana ; Carlini, Paolo ; Felici, Alessandra ; Mandalà, Mario ; Papaldo, Paola ; Fabi, Alessandra ; Ciccarese, Mariangela ; Cuppone, Federica ; Cecere, Fabiana Letizia ; Nuzzo, Carmen ; Terzoli, Edmondo ; Cognetti, Francesco. / Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. In: Chest. 2006 ; Vol. 130, No. 6. pp. 1808-1816.
@article{99e8f1a188b04bd6a057d3f34efe44b9,
title = "Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?",
abstract = "Purpose: To evaluate whether the incidence of recurrent venous thromboembolism (VTE) events after therapy differs for patients treated with long-term low-molecular-weight heparin (LMWH) or oral anticoagulant therapy (OAT). Methods: All randomized studies were searched through computerized queries of MEDLINE, the Cochrane Controlled Trials Register, the American Society of Hematology abstract database, and the American Society of Clinical Oncology abstract database. Results: Eleven studies including 2,907 patients were identified. Seven studies evaluated a period of 3 to 9 months after cessation of the allocated treatment: 5.4{\%} of patients in the LMWH group vs 4{\%} in the arm allocated to OAT had an episode of recurrent symptomatic VTE. Combined analysis showed a nonsignificant trend in lowering recurrent symptomatic VTE in favor of OAT (relative risk [RR], 1.29; 95{\%} confidence interval [CI], 0.82 to 2.02; p = 0.27). By contrast, during active treatment, a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT was registered (RR, 0.63; 95{\%} CI, 0.47 to 0.83; p = 0.001). Regarding cancer patients only, 37 of 569 patients (6.5{\%}) in the LMWH group had recurrent symptomatic VTE vs 69 of 546 patients (12.6{\%}) in the OAT group, with a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH (RR, 0.52; 95{\%} CI, 0.35 to 0.76; p = 0.001). Conclusions: Despite the significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT during treatment, patients treated with long-term LMWH do not seem to have more frequently recurrent VTE events compared with OAT after cessation of therapy. The significant difference favoring LMWH over OAT among all patients receiving treatment comes mostly from studies enrolling cancer patients.",
keywords = "Deep vein thrombosis, Low-molecular-weight heparin, Oral anticoagulant therapy, Venous thromboembolism, Vitamin K antagonists",
author = "Gianluigi Ferretti and Emilio Bria and Diana Giannarelli and Paolo Carlini and Alessandra Felici and Mario Mandal{\`a} and Paola Papaldo and Alessandra Fabi and Mariangela Ciccarese and Federica Cuppone and Cecere, {Fabiana Letizia} and Carmen Nuzzo and Edmondo Terzoli and Francesco Cognetti",
year = "2006",
month = "12",
doi = "10.1378/chest.130.6.1808",
language = "English",
volume = "130",
pages = "1808--1816",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?

AU - Ferretti, Gianluigi

AU - Bria, Emilio

AU - Giannarelli, Diana

AU - Carlini, Paolo

AU - Felici, Alessandra

AU - Mandalà, Mario

AU - Papaldo, Paola

AU - Fabi, Alessandra

AU - Ciccarese, Mariangela

AU - Cuppone, Federica

AU - Cecere, Fabiana Letizia

AU - Nuzzo, Carmen

AU - Terzoli, Edmondo

AU - Cognetti, Francesco

PY - 2006/12

Y1 - 2006/12

N2 - Purpose: To evaluate whether the incidence of recurrent venous thromboembolism (VTE) events after therapy differs for patients treated with long-term low-molecular-weight heparin (LMWH) or oral anticoagulant therapy (OAT). Methods: All randomized studies were searched through computerized queries of MEDLINE, the Cochrane Controlled Trials Register, the American Society of Hematology abstract database, and the American Society of Clinical Oncology abstract database. Results: Eleven studies including 2,907 patients were identified. Seven studies evaluated a period of 3 to 9 months after cessation of the allocated treatment: 5.4% of patients in the LMWH group vs 4% in the arm allocated to OAT had an episode of recurrent symptomatic VTE. Combined analysis showed a nonsignificant trend in lowering recurrent symptomatic VTE in favor of OAT (relative risk [RR], 1.29; 95% confidence interval [CI], 0.82 to 2.02; p = 0.27). By contrast, during active treatment, a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT was registered (RR, 0.63; 95% CI, 0.47 to 0.83; p = 0.001). Regarding cancer patients only, 37 of 569 patients (6.5%) in the LMWH group had recurrent symptomatic VTE vs 69 of 546 patients (12.6%) in the OAT group, with a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH (RR, 0.52; 95% CI, 0.35 to 0.76; p = 0.001). Conclusions: Despite the significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT during treatment, patients treated with long-term LMWH do not seem to have more frequently recurrent VTE events compared with OAT after cessation of therapy. The significant difference favoring LMWH over OAT among all patients receiving treatment comes mostly from studies enrolling cancer patients.

AB - Purpose: To evaluate whether the incidence of recurrent venous thromboembolism (VTE) events after therapy differs for patients treated with long-term low-molecular-weight heparin (LMWH) or oral anticoagulant therapy (OAT). Methods: All randomized studies were searched through computerized queries of MEDLINE, the Cochrane Controlled Trials Register, the American Society of Hematology abstract database, and the American Society of Clinical Oncology abstract database. Results: Eleven studies including 2,907 patients were identified. Seven studies evaluated a period of 3 to 9 months after cessation of the allocated treatment: 5.4% of patients in the LMWH group vs 4% in the arm allocated to OAT had an episode of recurrent symptomatic VTE. Combined analysis showed a nonsignificant trend in lowering recurrent symptomatic VTE in favor of OAT (relative risk [RR], 1.29; 95% confidence interval [CI], 0.82 to 2.02; p = 0.27). By contrast, during active treatment, a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT was registered (RR, 0.63; 95% CI, 0.47 to 0.83; p = 0.001). Regarding cancer patients only, 37 of 569 patients (6.5%) in the LMWH group had recurrent symptomatic VTE vs 69 of 546 patients (12.6%) in the OAT group, with a statistically significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH (RR, 0.52; 95% CI, 0.35 to 0.76; p = 0.001). Conclusions: Despite the significant reduction of the risk of recurrent symptomatic VTE in favor of LMWH over OAT during treatment, patients treated with long-term LMWH do not seem to have more frequently recurrent VTE events compared with OAT after cessation of therapy. The significant difference favoring LMWH over OAT among all patients receiving treatment comes mostly from studies enrolling cancer patients.

KW - Deep vein thrombosis

KW - Low-molecular-weight heparin

KW - Oral anticoagulant therapy

KW - Venous thromboembolism

KW - Vitamin K antagonists

UR - http://www.scopus.com/inward/record.url?scp=33845959873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845959873&partnerID=8YFLogxK

U2 - 10.1378/chest.130.6.1808

DO - 10.1378/chest.130.6.1808

M3 - Article

C2 - 17167001

AN - SCOPUS:33845959873

VL - 130

SP - 1808

EP - 1816

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -

Access to Document